about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Lil­ly's Trulic­i­ty CV out­comes da­ta un­der­whelm amid block­buster di­a­betes ri­val­ry with No­vo

6 years ago
Pharma

Stick­ing to hottest trends in bio­phar­ma, On­colo­gie gath­ers $80M for next leg of trans-Pa­cif­ic clin­i­cal jour­ney

6 years ago
Startups

Ar­ti­zan com­pletes mi­cro­bio­me starter pack­age with Brii deal, CSO hire and some mon­ey to dash for the clin­ic

6 years ago
Financing
Startups

'We kept at it': Jef­frey Blue­stone plots late-stage come­back af­ter teplizum­ab shown to de­lay type 1 di­a­betes

6 years ago
R&D

Ot­su­ka scores PhI­II win for an­oth­er As­tex drug; GSK ex­pands Nu­cala use in asth­ma

6 years ago
News Briefing

La Jol­la whips up some love for iron over­load drug with promis­ing da­ta snap­shot

6 years ago
R&D

As in­vestor con­fi­dence crum­bles fol­low­ing fund sus­pen­sion, Neil Wood­ford faces back­lash on fees

6 years ago
Pharma

Pro­tal­ix, Chiesi fire up ac­cel­er­at­ed ap­proval pitch for Fab­ry dis­ease treat­ment

6 years ago
R&D

As­traZeneca stocks up on Calquence am­mu­ni­tion for big BTK ri­val­ry with J&J, Ab­b­Vie

6 years ago
R&D

Pfiz­er scoops Cal­i­co ex­ec Jeff Set­tle­man to head big on­col­o­gy R&D ops in La Jol­la

6 years ago

Clock starts tick­ing on Leif Jo­hansson's re­tire­ment from As­traZeneca chair­man role — re­port

6 years ago
People

Ned Sharp­less weighs in on gene ther­a­py pric­ing de­bate, sug­gest­ing 'the mes­sag­ing got lost'

6 years ago
People
Cell/Gene Tx

Texas biotech Lung Ther­a­peu­tics clos­es $36M Se­ries C to ad­vance clin­i­cal work for or­phan drugs

6 years ago
R&D

Spread­ing its wings in Chi­na with glob­al am­bi­tion, EpimAb snags $74M Se­ries B for bis­pe­cif­ic work

6 years ago
Financing
China

Neil Wood­ford force­ful­ly stems in­vestor out­flow by sus­pend­ing his be­lea­guered main fund

6 years ago
People
Financing

Bay­er en­lists Arv­inas on two-pronged pro­tein degra­da­tion ef­fort, for­ay­ing in­to agtech

6 years ago

Mer­ck tests an­tibi­otics wa­ters again as FDA OKs Zer­bax­a's ex­pand­ed use in pneu­mo­nia

6 years ago
Pharma

Add one fa­tal flaw to Jiankui He's litany of mis­takes in CRISPR ba­by de­ba­cle

7 years ago
People
Discovery

EU stamps his­toric OK on blue­bird’s gene ther­a­py for β-tha­lassemia — now sit back and wait for the price

7 years ago
R&D
Cell/Gene Tx

J&J, Gen­mab strength­en case for Darza­lex in front­line mul­ti­ple myelo­ma with fresh slate of PhI­II da­ta

7 years ago
R&D

Vi­cal finds way out of R&D woes via re­verse merg­er with der­ma­tol­ogy biotech Brick­ell

7 years ago
Deals

Fast mov­ing Chi­nese reg­u­la­tors wave third home­grown PD-1 to mar­ket

7 years ago
China

Aslan dou­bles down on CSL drug, plots long­shot ri­val­ry with Dupix­ent in atopic der­mati­tis

7 years ago
R&D

Ned Sharp­less slammed with crit­i­cal let­ter from a key De­mo­c­ra­t­ic Sen­a­tor un­hap­py with e-cig poli­cies

7 years ago
People
First page Previous page 979899100101102103 Next page Last page
A service from the Financial Times